JUNO Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) Investors

BOSTON, Oct. 31, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) that it is investigating legal claims against the company for possible securities fraud violations committed by JUNO THERAPEUTICS, INC. (NASDAQ: JUNO).

JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) investors are urged to contact our law firm immediately to protect their rights. Visit our JUNO Shareholder Lawsuit website or call 1-800-934-2921 to speak to someone about your case.

The investigation concerns possible violations of securities law committed by JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) management that has led to significant losses to investors. These possible violations stem from allegations from a recent lawsuit that JUNO executives may have misled investors about the prospects of a new cancer drug, JCAR015.

Kyros Law Offices urges JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) investors to contact our law firm immediately to protect their rights. Visit our JUNO Shareholder Lawsuit website or call 1-800-934-2921 to find out if you have a case.

Kyros Law specializes in a wide range of complex litigation, mass torts, and corporate governance matters, including the representation of whistleblowers, shareholders and consumers in securities fraud, false claims act and class actions. Our lawyers have been responsible for recovering hundreds of millions of dollars for our clients throughout the United States, Africa, Asia and Europe. Visit our website to learn more about our firm.

SOURCE Kyros Law